Bayer Reports Results of Nifurtimox in P-III CHICO Study for Chagas Disease in Pediatric Patients
Shots:
- TheP-III CHICO study involves assessing of Nifurtimox (120mg/30mg) vs PBO in 330 pediatric patients with acute or chronic Chagas disease across 25 sites including Argentina- Bolivia- and Colombia
- The P-III CHICO study results: met its 1EPs; superior serological response @60days treatment; safe profile at body weight-adjusted dosing
- Nifurtimox (120mg- 30mg) is a nitro heterocyclic compound available as dispersible tablets used for easy division and improvement in weight adjusted dosing in newborns- infants- and children
Ref: Bayer | Image: Reuters Africa
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com